AB SCIENCE news, videos and press releases
For more news please use our advanced search feature.
AB SCIENCE - More news...
AB SCIENCE - More news...
- AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
- AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
- AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
- AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
- AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
- AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
- AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
- AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
- AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
- AB Science announces the success of its capital increase by private placement for an amount of 15 million euros
- AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
- AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
- AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
- AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
- AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
- AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
- AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
- Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
- AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
- AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
- AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
- AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
- AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
- AB Science announces the financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
- AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
- AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency
- AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
- AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
- AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
- AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS